openPR Logo
Press release

Focal Segmental Glomerulosclerosis (FSGS) Market: Launch of Pipeline Products in Foreseeable Future to Change Market Dynamics

06-13-2018 10:54 PM CET | Health & Medicine

Press release from: Transparency Market Research

Focal Segmental Glomerulosclerosis (FSGS) Market: Launch

Focal segmental glomerulosclerosis Market: Snapshot

Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on rare diseases too are proving beneficial for the market for focal segmental glomerulosclerosis.

Rising at a 8.0% CAGR from 2017 to 2025, the global focal segmental glomerulosclerosis (FSGS) market will likely become worth US$15.83 bn by 2025-end fromUS$7.82 bn in 2016, finds a report by Transparency Market Research.

Get PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31505

Primary Focal Segmental Glomerulosclerosis Garners Greater Market Share due to Awareness About it

Depending upon the disease type, the market can be bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Of the two, the segment of primary focal segmental glomerulosclerosis held a mammoth 79.8% share in the market in 2016. Also known as primary idiopathic/genetic focal segmental glomerulosclerosis, primary focal segmental glomerulosclerosis is a kind of the focal segmental glomerulosclerosis disease without a known or obvious cause. Growing awareness about the disease and its management is at the forefront of driving growth in the segment.

Depending upon the management of the disease, the global market for focal segmental glomerulosclerosis (FSGS) can again be split broadly into diagnosis and treatment. The segment of diagnosis can be further divided into creatine test, kidney biopsy, etc. The segment of treatment again can be further divided into drug therapy, kidney transplant, and dialysis. At present, the treatment segment contributes to most of the revenue in the market for focal segmental glomerulosclerosis (FSGS). This is because of the massive unmet requirements in the market. A promising pipeline of novel molecules and their approval will continue boosting the segment in the next couple of years.

Get Sample Copy of The Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31505

Considerable Penetration of Treatment Drives U.S. Market to Fore

Geographically, North America accounts for a leading share in the market for focal segmental glomerulosclerosis because of the presence of a properly structured health care industry and availability of reimbursement policies with wider coverage. The U.S. is mainly serving to drive the market in North America due to the greater uptake of advanced and high-cost drug therapies, considerable penetration of treatment, and helpful reimbursement policies. Another factor stoking market growth in the U.S. is the classification of focal segmental glomerulosclerosis (FSGS) drugs under orphan disease drugs categories – companies involved in the production and clinical trials of drugs for orphan diseases receive exemption from payment of new drug application fee, provision of tax credits on clinical research, waivers for post-approval annual establishment and product fees, and exclusive marketing rights up to a period of seven years.

Europe trails North America in terms of market share. In 2016, the segment accounted for a share of 25.5%. Vis-à-vis growth rate, Asia Pacific is expected to outshine all other regions. The market in the region is being powered primarily by China which in turn is being propelled by the increasing diagnosis rate of focal segmental glomerulosclerosis, stupendous growth in the healthcare industry, and availability of drugs and dialysis at a lower price.

Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.

Get Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=31505

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Focal Segmental Glomerulosclerosis (FSGS) Market: Launch of Pipeline Products in Foreseeable Future to Change Market Dynamics here

News-ID: 1081493 • Views: 475

More Releases from Transparency Market Research

Glioblastoma Multiforme Treatment (GBM) Market Demand Research Report Analysis B …
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and
Genomics Personalized Health Market Trends Research Report Analysis Revealing Ke …
The global genomics personalized health market is anticpated to be highly fragmented due to presence of large number of palyers in the regional and global market. Some of the key players in the industry are Thermo Fisher Scientific, Inc., QIAGEN, Illumina, Inc., Bio-Rad Laboratories, Inc., Lonza Group, F. Hoffmann-La Roche AG, INVITAE Corporation, Interleukin Genetics Inc., Genetic Technologies Limited, Eastern Biotech and Life Sciences, uBiome, Inc., DNA Genotek Inc. which
Impact of Outbreak of COVID-19 on Antiseptic and Disinfectant Market : Global In …
The global antiseptic and disinfectant market was valued at US$ 6.3 Bn in 2017. It is projected to expand at a compound annual growth rate (CAGR) of 6.2% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled “Antiseptic and Disinfectant Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. The report suggests that rising awareness regarding home cleanliness and the need
Life Science Reagents Market Shows Strong Growth Forecast 2019–2027
Transparency Market Research (TMR) has published a new report on the life science reagents market for the forecast period of 2019–2027. According to the report, the global life science reagents market was valued at around US$ 37,000 Mn in 2018, and is projected to expand at a CAGR of nearly 8% from 2019 to 2027. Life science reagents play a critical role in the manufacturing and testing of pharmaceutical products, cell-based

All 5 Releases


More Releases for FSGS

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population. Download the sample report @ https://www.pharmaproff.com/request-sample/1090 FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two
Focal Segmental Glomerulosclerosis (FSGS) Market: to expand at a healthy CAGR fr …
Focal segmental glomerulosclerosis Market: Snapshot Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on
Global Focal Segmental Glomerulosclerosis (FSGS) Market to Grow at 8% CAGR throu …
A new comprehensive study titled “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” has recently been added to the vast database of Market Research Reports Search Engine (MRRSE). The global focal segmental glomerulosclerosis (FSGS) market is likely to grow at a CAGR of 8% during the assessment period, and surpass US$ 15 Bn in terms of revenues. Download Sample Copy in a PDF
Global Focal Segmental Glomerulosclerosis (FSGS) Market: Industry Development Sc …
Market Research Report Search Engine (MRRSE) recently announced the addition of a new research study to its comprehensive collection of research reports. The research report, titled “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” offers a detailed analysis of the market providing insights into the market dynamics that are expected to influence the overall market positively in the next few years. Furthermore,
Focal Segmental Glomerulosclerosis (FSGS) Market: Comprehensive Analysis and Fut …
A latest research report titled as “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025”. has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or
Global Focal Segmental Glomerulosclerosis (FSGS) Market Anticipated to Surge at …
New research report offers a comprehensive analysis of the “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market. Request to view Sample Report @ https://www.mrrse.com/sample/4351 Global Focal segmental glomerulosclerosis (FSGS) Market: Snapshot Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients